Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FOLFOX + sunitinib
- Development stage
- Discontinued
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
FOLFOX + sunitinib is a combination regimen consisting of the chemotherapy protocol FOLFOX (folinic acid, fluorouracil, and oxaliplatin) plus the targeted therapy sunitinib. - **FOLFOX** is a standard chemotherapy regimen primarily used for colorectal cancer. It combines three drugs: - Folinic acid (leucovorin): enhances the effectiveness of fluorouracil. - Fluorouracil (5-FU): an antimetabolite that inhibits DNA synthesis in rapidly dividing cells. - Oxaliplatin: a platinum-based agent that causes DNA crosslinking and apoptosis in cancer cells[1][2][4][7]. - **Sunitinib** is an oral small molecule tyrosine kinase inhibitor targeting multiple receptors including vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), KIT, FLT3, RET, and CSF1R. It inhibits tumor angiogenesis and cell proliferation. This combination aims to leverage both cytotoxic effects from chemotherapy and antiangiogenic/targeted effects from sunitinib for enhanced anticancer activity.
- Brand names
- Eloxatin
- Other names
- folinic acid + fluorouracil + oxaliplatin + sunitinib
02
Targets
CSF1R (Macrophage colony-stimulating factor receptor)DNAFLT3 (Fms related receptor tyrosine kinase 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)RET (Rearranged during transfection receptor tyrosine kinase)TS (Thymidylate synthase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on FOLFOX + sunitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FOLFOX + sunitinib.